drugset
drugset / Trial / NCT04758234

A Study of LY3549492 in Healthy Participants

NCT04758234 ↗

Phase 1 Completed 54 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening.

Timeline

Start
2021-02-22
Primary completion
2022-01-10
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3549492 Unknown — Oral

Indications

No indication recorded.